OSSIO

OSSIO is a privately-held medical device company founded in 2014, targeting the multi-billion dollar orthopedic fixation market with its OSSIOfiber® technology platform. The company's implants are engineered from a continuous mineral fiber matrix that provides initial strength comparable to metal but is fully replaced by natural bone over 18-24 months. With commercial headquarters near Boston and R&D/manufacturing in Israel, OSSIO is in the commercial stage, initially focused on foot and ankle applications, with plans to expand its portfolio. Its value proposition addresses patient dissatisfaction with metal implants, surgeon demand for biologically friendly options, and payor interest in reducing long-term complication costs.

OSSIO's technology platform is the OSSIOfiber® Intelligent Bone Regeneration Technology, a proprietary continuous natural mineral fiber matrix. It is engineered to provide initial strength greater than cortical bone for secure fixation, while its bio-integrative design allows it to be fully resorbed and replaced by native bone within 18-24 months, leaving no permanent implant behind.

OSSIO competes in the orthopedic fixation market against dominant players like Johnson & Johnson (DePuy Synthes), Stryker, and Zimmer Biomet, which primarily sell metal implants. It also competes with older-generation bioresorbable polymer implants, which often lack sufficient strength and can cause inflammatory reactions. OSSIO's differentiation is its unique bio-integrative mineral matrix that aims to combine the strength of metal with the complete resorption of an ideal biologic.